Ye Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ye Wu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Xin Luan
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
9 shared publications - Wei-Dong Zhang
School of Pharmacy, Naval Medical University, Shanghai, China
6 shared publications Jiayi Lin
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
5 shared publicationsShengxin Lu
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
5 shared publications- Dale George Nagle
Shanghai Jiao Tong University, Shanghai, PR China
4 shared publications Xiaokun Zhang
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
4 shared publications
Latest Publications
- 31 August 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (11) , 6744-6752
A GSH-responsive stapled oncolytic peptide-STING agonist conjugate for tumor-selective immunotherapy
- 31 August 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (11) , 6744-6752
A GSH-responsive stapled oncolytic peptide-STING agonist conjugate for tumor-selective immunotherapy
- 28 May 2026
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 24 (6) , 696-709
Naturally derived oncolytic peptides: from discovery to clinical translation
- 28 May 2026
- Published by Elsevier in Chinese Journal of Natural Medicines
- Vol. 24 (6) , 696-709
Naturally derived oncolytic peptides: from discovery to clinical translation
- Open Access
- 12 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (44) , e75652
Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy
Oncolytic peptides (OPs) represent a promising class of cancer therapeutics capable of rapidly lysing tumor cells and activating antitumor immunity. However, accurate in silico identification of potent OPs remains challenging due to limited datasets and high false‐positive rates. Here, we present MISPOP (Mechanism‐Informed Screening Pipeline for Oncolytic Peptides), an integrated machine learning framework that combines eXtreme Gradient Boosting, deep neural networks, and transfer learning into a high‐confidence ensemble model augmented with physicochemical priors. Applied to a natural peptide library of 1033 sequences, MISPOP prioritized 16 candidates, among which five were synthesized and evaluated across three tumor cell lines. Dermaseptin‐S9 exhibited the most favorable therapeutic index. Molecular dynamics simulations revealed its deep insertion into lipid bilayers and stable peptide‐membrane interactions, while in vitro assays confirmed pronounced membrane disruption and induction of immunogenic cell death. In a B16F10 melanoma model, Dermaseptin‐S9 achieved over 92% tumor growth inhibition without evident systemic toxicity. Collectively, these findings demonstrate that embedding biochemical priors into ensemble learning can markedly improve predictive accuracy and enable the discovery of potent OPs, offering a generalizable paradigm for accelerating peptide‐based oncotherapy development.
- 12 May 2026
- Published by Wiley in Advanced Science
- Vol. 13 (44) , e75652
Open AccessMechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy
Oncolytic peptides (OPs) represent a promising class of cancer therapeutics capable of rapidly lysing tumor cells and activating antitumor immunity. However, accurate in silico identification of potent OPs remains challenging due to limited datasets and high false‐positive rates. Here, we present MISPOP (Mechanism‐Informed Screening Pipeline for Oncolytic Peptides), an integrated machine learning framework that combines eXtreme Gradient Boosting, deep neural networks, and transfer learning into a high‐confidence ensemble model augmented with physicochemical priors. Applied to a natural peptide library of 1033 sequences, MISPOP prioritized 16 candidates, among which five were synthesized and evaluated across three tumor cell lines. Dermaseptin‐S9 exhibited the most favorable therapeutic index. Molecular dynamics simulations revealed its deep insertion into lipid bilayers and stable peptide‐membrane interactions, while in vitro assays confirmed pronounced membrane disruption and induction of immunogenic cell death. In a B16F10 melanoma model, Dermaseptin‐S9 achieved over 92% tumor growth inhibition without evident systemic toxicity. Collectively, these findings demonstrate that embedding biochemical priors into ensemble learning can markedly improve predictive accuracy and enable the discovery of potent OPs, offering a generalizable paradigm for accelerating peptide‐based oncotherapy development.
- 19 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113717
Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy
- 19 April 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 382, 113717
Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy
- Open Access
- 29 April 2024
- Published by Wiley in Advanced Science
- Vol. 11 (26) , e2308435
In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77‐PPARγ Interaction and Its Anti‐Breast‐Cancer Efficacy
The binding of peroxisome proliferator‐activated receptor γ (PPARγ) to the orphan nuclear receptor Nur77 facilitates the ubiquitination and degradation of Nur77, and leads to aberrant fatty acid uptake for breast cancer progression. Because of its crucial role in clinical prognosis, the interaction between Nur77 and PPARγ is an attractive target for anti‐breast‐cancer therapy. However, developing an inhibitor of the Nur77‐PPARγ interaction poses a technical challenge due to the absence of the crystal structure of PPARγ and its corresponding interactive model with Nur77. Here, ST‐CY14, a stapled peptide, is identified as a potent modulator of Nur77 with a KD value of 3.247 × 10−8 M by in silico analysis, rational design, and structural modification. ST‐CY14 effectively increases Nur77 protein levels by blocking the Nur77‐PPARγ interaction, thereby inhibiting lipid metabolism in breast tumor cells. Notably, ST‐CY14 significantly suppresses breast cancer growth and bone metastasis in mice. The findings demonstrate the feasibility of exploiting directly Nur77‐PPARγ interaction in breast cancer, and generate what to the best knowledge is the first direct inhibitor of the Nur77‐PPARγ interaction available for impeding fatty acid uptake and therapeutic development.
- 29 April 2024
- Published by Wiley in Advanced Science
- Vol. 11 (26) , e2308435
Open AccessIn Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77‐PPARγ Interaction and Its Anti‐Breast‐Cancer Efficacy
The binding of peroxisome proliferator‐activated receptor γ (PPARγ) to the orphan nuclear receptor Nur77 facilitates the ubiquitination and degradation of Nur77, and leads to aberrant fatty acid uptake for breast cancer progression. Because of its crucial role in clinical prognosis, the interaction between Nur77 and PPARγ is an attractive target for anti‐breast‐cancer therapy. However, developing an inhibitor of the Nur77‐PPARγ interaction poses a technical challenge due to the absence of the crystal structure of PPARγ and its corresponding interactive model with Nur77. Here, ST‐CY14, a stapled peptide, is identified as a potent modulator of Nur77 with a KD value of 3.247 × 10−8 M by in silico analysis, rational design, and structural modification. ST‐CY14 effectively increases Nur77 protein levels by blocking the Nur77‐PPARγ interaction, thereby inhibiting lipid metabolism in breast tumor cells. Notably, ST‐CY14 significantly suppresses breast cancer growth and bone metastasis in mice. The findings demonstrate the feasibility of exploiting directly Nur77‐PPARγ interaction in breast cancer, and generate what to the best knowledge is the first direct inhibitor of the Nur77‐PPARγ interaction available for impeding fatty acid uptake and therapeutic development.
- Open Access
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (7) , 2779-2789
Seleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy
Selenium (Se) is an essential trace element for biological processes. Seleno-amino acids (Se-AAs), known as the organic forms of Se, and their metabolic reprogramming have been increasingly recognized to regulate antioxidant defense, enzyme activity, and tumorigenesis. Therefore, there is emerging interest in exploring the potential application of Se-AAs in antitumor therapy. In addition to playing a vital role in inhibiting tumor growth, accumulating evidence has revealed that Se-AA metabolism could reshape the tumor microenvironment (TME) and enhance immunotherapy responses. This review presents a comprehensive overview of the current progress in multifunctional Se-AAs for antitumor treatment, with a particular emphasis on elucidating the crosstalk between Se-AA metabolism and various cell types in the TME, including tumor cells, T cells, macrophages, and natural killer cells. Furthermore, novel applications integrating Se-AAs are also discussed alongside prospects to provide new insights into this emerging field.
- 1 January 2024
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 20 (7) , 2779-2789
Open AccessSeleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy
Selenium (Se) is an essential trace element for biological processes. Seleno-amino acids (Se-AAs), known as the organic forms of Se, and their metabolic reprogramming have been increasingly recognized to regulate antioxidant defense, enzyme activity, and tumorigenesis. Therefore, there is emerging interest in exploring the potential application of Se-AAs in antitumor therapy. In addition to playing a vital role in inhibiting tumor growth, accumulating evidence has revealed that Se-AA metabolism could reshape the tumor microenvironment (TME) and enhance immunotherapy responses. This review presents a comprehensive overview of the current progress in multifunctional Se-AAs for antitumor treatment, with a particular emphasis on elucidating the crosstalk between Se-AA metabolism and various cell types in the TME, including tumor cells, T cells, macrophages, and natural killer cells. Furthermore, novel applications integrating Se-AAs are also discussed alongside prospects to provide new insights into this emerging field.
- Open Access
- 7 February 2023
- Published by Wiley in Cancer Science
- Vol. 114 (5) , 1958-1971
Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
As one of the common malignant cancer types, gastric cancer (GC) is known for late‐stage diagnosis and poor prognosis. Overexpression of the receptor tyrosine kinase MET is associated with poor prognosis among patients with advanced stage GC. However, no MET inhibitor has been used for GC treatment. Like other tyrosine kinase inhibitors that fit the “occupancy‐driven” model, current MET inhibitors are prone to acquired resistance. The emerging proteolysis targeting chimera (PROTAC) strategy could overcome such limitations through direct degradation of the target proteins. In this study, we successfully transformed the MET‐targeted inhibitor crizotinib into a series of PROTACs, recruiting cereblon/cullin 4A E3 ubiquitin ligase to degrade the MET proteins. The optimized lead PROTAC (PRO‐6 E) effectively eliminated MET proteins in vitro and in vivo, inhibiting proliferation and motility of MET‐positive GC cells. In the MKN‐45 xenograft model, PRO‐6 E showed pronounced antitumor efficacy with a well‐tolerated dosage regimen. These results validated PRO‐6 E as the first oral PROTAC for MET‐dependent GC.
- 7 February 2023
- Published by Wiley in Cancer Science
- Vol. 114 (5) , 1958-1971
Open AccessCrizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
As one of the common malignant cancer types, gastric cancer (GC) is known for late‐stage diagnosis and poor prognosis. Overexpression of the receptor tyrosine kinase MET is associated with poor prognosis among patients with advanced stage GC. However, no MET inhibitor has been used for GC treatment. Like other tyrosine kinase inhibitors that fit the “occupancy‐driven” model, current MET inhibitors are prone to acquired resistance. The emerging proteolysis targeting chimera (PROTAC) strategy could overcome such limitations through direct degradation of the target proteins. In this study, we successfully transformed the MET‐targeted inhibitor crizotinib into a series of PROTACs, recruiting cereblon/cullin 4A E3 ubiquitin ligase to degrade the MET proteins. The optimized lead PROTAC (PRO‐6 E) effectively eliminated MET proteins in vitro and in vivo, inhibiting proliferation and motility of MET‐positive GC cells. In the MKN‐45 xenograft model, PRO‐6 E showed pronounced antitumor efficacy with a well‐tolerated dosage regimen. These results validated PRO‐6 E as the first oral PROTAC for MET‐dependent GC.
- Open Access
- 22 November 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (22)
Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
The aberrant activation of STAT3 is associated with the etiology and progression in a variety of malignant epithelial-derived tumors, including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Due to the lack of an enzymatic catalytic site or a ligand-binding pocket, there are no small-molecule inhibitors directly targeting STAT3 that have been approved for clinical translation. Emerging proteolysis targeting chimeric (PROTAC) technology–based approach represents a potential strategy to overcome the limitations of conventional inhibitors and inhibit activation of STAT3 and downstream genes. In this study, the heterobifunctional small-molecule–based PROTACs are successfully prepared from toosendanin (TSN), with 1 portion binding to STAT3 and the other portion binding to an E3 ubiquitin ligase. The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO). The following mechanistic investigation identifies the reduced expression of critical downstream STAT3 effectors, through which TSM-1 promotes cell cycle arrest and apoptosis in tumor cells. These findings provide the first demonstration to our knowledge of a successful PROTAC-targeting strategy in STAT3-dependent epithelial cancer.
- 22 November 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (22)
Open AccessSmall-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
The aberrant activation of STAT3 is associated with the etiology and progression in a variety of malignant epithelial-derived tumors, including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Due to the lack of an enzymatic catalytic site or a ligand-binding pocket, there are no small-molecule inhibitors directly targeting STAT3 that have been approved for clinical translation. Emerging proteolysis targeting chimeric (PROTAC) technology–based approach represents a potential strategy to overcome the limitations of conventional inhibitors and inhibit activation of STAT3 and downstream genes. In this study, the heterobifunctional small-molecule–based PROTACs are successfully prepared from toosendanin (TSN), with 1 portion binding to STAT3 and the other portion binding to an E3 ubiquitin ligase. The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO). The following mechanistic investigation identifies the reduced expression of critical downstream STAT3 effectors, through which TSM-1 promotes cell cycle arrest and apoptosis in tumor cells. These findings provide the first demonstration to our knowledge of a successful PROTAC-targeting strategy in STAT3-dependent epithelial cancer.
- Open Access
- 1 January 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (7) , 3456-3473
Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
Rationale: Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically.
- 1 January 2022
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (7) , 3456-3473
Open AccessPolymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer
Rationale: Scarce tumor mutation burden and neoantigens create tremendous obstacles for an effective immunotherapy of colorectal cancer (CRC). Oncolytic peptides rise as a promising therapeutic approach that boosts tumor-specific immune responses by inducing antigenic substances. However, the clinical application of oncolytic peptides has been hindered because of structural instability, proteolytic degradation, and undesired toxicity when administered systemically.
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (17) , 8337-8349
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as “undruggable” before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (17) , 8337-8349
Open AccessEmerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as “undruggable” before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.